Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

Company Overview

Actinium Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML. The company also has exploratory programs leveraging its antibody‐targeted alpha‐conjugate (ATAC) platform in other hematologic and solid tumor indications. These programs are designed to advance precision oncology by combining the targeting specificity of antibodies with the high‐energy, short‐range properties of alpha‐emitting isotopes.

Actinium collaborates with leading academic research institutions to advance its clinical programs, and its development strategy is supported by orphan drug designations and fast‐track status from regulatory authorities. The company is incorporated in Delaware, headquartered in New York City, and conducts clinical trials primarily in the United States. Its management team brings expertise in oncology drug development, radiochemistry, and regulatory affairs to drive its late‐stage assets toward potential commercialization.

Key Stats

• Today's Range: $1.19 to $1.29
• 50-Day Range: $0.98 to $1.52
• 52-Week Range: $0.95 to $1.95
• Volume: 131,972 shs
• Average Volume: 161,762 shs
• Market Capitalization: $39.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

Actinium Pharmaceuticals Stock Analysis - MarketRank™

Actinium Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 581st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Actinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Actinium Pharmaceuticals has a consensus price target of $4.50, representing about 257.1% upside from its current price of $1.26.

Amount of Analyst Coverage

Actinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Actinium Pharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Actinium Pharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Actinium Pharmaceuticals has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATNM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Actinium Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Actinium Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for ATNM on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.60% of the stock of Actinium Pharmaceuticals is held by insiders.

Percentage Held by Institutions

27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

ATNM Stock Analysis - Frequently Asked Questions

How have ATNM shares performed this year?

Actinium Pharmaceuticals' stock was trading at $1.36 at the start of the year. Since then, ATNM stock has decreased by 7.4% and is now trading at $1.26.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) announced its earnings results on Monday, August, 5th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02.

When did Actinium Pharmaceuticals' stock split?

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK),

Company Calendar

• Last Earnings: 8/05/2024
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ATNM
• Previous Symbol: NYSE:ATNM
• CIK: 1388320
• Web: N/A
• Phone: (646) 677-3870
• Fax: N/A
• Employees: 30
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Actinium Pharmaceuticals: $4.50
• High Price Target: $5.00
• Low Price Target: $4.00
• Potential Upside/Downside: +257.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.82 million
• Net Margins: N/A
• Pretax Margin: -50,512.35%
• Return on Equity: -100.85%
• Return on Assets: -47.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.25
• Quick Ratio: 10.25

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 439.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 0.96

Miscellaneous

• Outstanding Shares: 31,375,000
• Free Float: 29,324,000
• Market Cap: $39.53 million
• Optionable: Optionable
• Beta: -0.11